Market Challenges And Opportunities

Global Osteogenesis Imperfecta Treatment Market– Drivers

Rising demand for novel therapies for osteogenesis imperfecta treatment

Rising demand for novel therapies for osteogenesis imperfecta treatment is expected to the growth of global osteogenesis imperfecta market over the forecast period. For instance, in January 2020, Oncologie, Inc., an innovative biopharmaceutical company and Mereo BioPharma Group plc, a clinical-stage company focused on developing & commercializing rare disease & oncology treatments, entered into a license agreement to develop and commercialize ‘Navicixizumab.’ It is an anti-DLL4/VEGF bi-specific antibody for osteogenesis imperfecta treatment.

Strategic acquisition by the key market players

Strategic acquisition by the key market players to enhance the product portfolio by developing novel therapies is expected to drive the global osteogenesis imperfecta market over the forecast period. For instance, in February 2020, The Brittle Bone Disorders Consortium (BBDC) brings together physicians, researchers, and educators to learn more about osteogenesis imperfecta. The goal is to develop new and better treatments for patients with the disorder. Through research, the BBDC is discovering new biomarkers of the disease that will lead to a deeper understanding of underlying pathophysiology of osteogenesis imperfecta (OI) as well as assessing response to therapies. The BBDC also established a patient registry and helps to connect those who wish to get involved with support groups, research, and clinical trials. The partnership with the Osteogenesis Imperfecta Foundation and all of the families with OI is a critical component of the BBDC mission.

Strategic acquisition by the market key players

Non-availability of effective treatment for osteogenesis imperfecta

Global Osteogenesis Imperfecta Treatment Market: Restraints

Non-availability of effective treatment for osteogenesis imperfecta

Non-availability of effective treatment for osteogenesis imperfecta is expected to hinder the market growth over the forecast period. To avoid this, various innovation in the therapies is to be carried out for the effective treatment of OI. For instance, in March 2022, according to an article published in the Journal of British Orthopaedic Association by the Medscape, Bisphosphonates are drugs that have been used off label for the treatment of osteogenesis imperfecta (OI). Drugs in this class may slow the loss of existing bones and may reduce long bone fractures and vertebral compression. These drugs only reduces the bone fractures, but can’t treat the osteogenesis imperfecta and therefore, as such no cure is available for the OI.

Osteogenesis Imperfecta Treatment Market Report Snapshots